Onderzoek naar kenmerken in tumorweefsel en bloed, die informatie kunnen geven over de werkzaamheid van everolimus in combinatie met exemestaa

Recruiting

• Conditions: borstkanker, mammacarcinoom, gemetastaseerd, everolimus, exemestaan, biomarker.breast cancer, metastatic, everolimus, exemestane, biomarker.

• Registration Number: NL-OMON21846
• Lead Sponsor: VU University Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 175

Inclusion Criteria

Patients eligible for inclusion in this side-study have to meet all of the following criteria:

1.Adult women (> 18 years of age) with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.

Exclusion Criteria

Patients eligible for this study must not meet any of the following criteria:

1.HER2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Biomarker Evaluation from Primary Tumor Tissue, New Tumor Biopsies and Blood Samples.<br>Progression-free survival.

Secondary Outcome Measures

Name	Time	Method
umber of Participants with Adverse Events as a Measure of Safety and Tolerability